Floatz logo

Nivolumab

Invasive Bladder Giant Cell Urothelial Carcinoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 2/3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Invasive Bladder Giant Cell Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 2/3B
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2/3B
CIS-DIAMMINEDICHLOROPLATINUM II
Vasgene Therapeutics, Inc
Phase 2/3B
Relatlimab
National Cancer Institute (NCI)
Phase 2/3B
Recombinant Ephb4-Hsa Fusion Protein
Vasgene Therapeutics, Inc
Phase 2/3CCC

View all 15 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →